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Abstract
Introduction: Previous studies have shown that the number of myoblastically differentiated fibroblasts known as 
myofibroblasts (MFs) is significantly increased in stiff joint capsules, indicating their crucial role in the pathogenesis of 
post-traumatic joint stiffness. Although the mode of MFs' function has been well defined for different diseases 
associated with tissue fibrosis, the underlying mechanisms of their regulation in the pathogenesis of post-traumatic 
joint capsule contracture are largely unknown.
Methods: In this study, we examined the impact of the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α) 
on cellular functions of human joint capsule MFs. MFs were challenged with different concentrations of TNF-α with or 
without both its specifically inactivating antibody infliximab (IFX) and cyclooxygenase-2 (COX2) inhibitor diclofenac. 
Cell proliferation, gene expression of both alpha-smooth muscle actin (α-SMA) and collagen type I, the synthesis of 
prostaglandin derivates E2, F1A, and F2A, as well as the ability to contract the extracellular matrix were assayed in 
monolayers and in a three-dimensional collagen gel contraction model. The α-SMA and COX2 protein expressions 
were evaluated by immunofluorescence staining and Western blot analysis.
Results: The results indicate that TNF-α promotes cell viability and proliferation of MFs, but significantly inhibits the 
contraction of the extracellular matrix in a dose-dependent manner. This effect was associated with downregulation of 
α-SMA and collagen type I by TNF-α application. Furthermore, we found a significant time-dependent upregulation of 
prostaglandin E2 synthesis upon TNF-α treatment. The effect of TNF-α on COX2-positive MFs could be specifically 
prevented by IFX and partially reduced by the COX2 inhibitor diclofenac.
Conclusions: Our results provide evidence that TNF-α specifically modulates the function of MFs through regulation of 
prostaglandin E2 synthesis and therefore may play a crucial role in the pathogenesis of joint capsule contractures.
Introduction
Post-traumatic joint stiffness is a common complication
that occurs primarily after injuries of the upper extremities
involving articular structures [1,2]. In the majority of cases,
loss of function after trauma is due to adhesions and con-
tractions as well as to scar formation within capsulo-liga-
mentous structures. Upon injury, fibroblasts of the
surrounding tissue become activated, start to proliferate,
and undergo a phenotypic differentiation into contractile
myofibroblasts (MFs) [3]. Differentiated MFs are charac-
terized by the expression of alpha-smooth muscle actin (α-
SMA), a protein that is associated with the contractile phe-
notype of this cell type [4-6], as well as the synthesis of
proteins over the course of the healing process [5-8].
Although the underlying mechanisms of joint capsule con-
tracture are still poorly understood on the cellular level, the
activation and differentiation of MFs seem to be controlled
by a complex tissue-specific network of growth factors and
cytokines [3,9]. Mechanical stress, ED-A (extra domain A)
fibronectin, and transforming growth factor-beta 1 (TGF-
β1) are potent inducers of α-SMA expression and thus are
considered to be pro-fibrotic factors [3,5,6,10,11]. The
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complex interaction of different growth factors, cytokines,
and extracellular matrix (ECM) may create an environment
with an abnormal cytokine profile, which triggers the
excessive formation of MFs followed by high matrix turn-
over. In this context, numerous fibroconnective disorders
[8,10] such as Dupuytren contracture [12,13], carpal tunnel
syndrome [14], and frozen shoulder [15] have been associ-
ated with the appearance of MFs.
Until now, it has not been clear whether a specific inhibi-
tion of certain cytokines would be beneficial for prevention
of unrestricted MF activation. The pro-inflammatory
cytokine tumor necrosis factor-alpha (TNF-α) has aroused
our interest as a potential target molecule since the results
of recent studies have demonstrated its antagonistic activity
against the pro-fibrotic factor TGF-β1 [16-18]. These find-
ings, however, still need further confirmation as the effect
of TNF-α may be site- as well as organ-specific. TNF-α
may exert direct cellular effects on TGF-β1 expression, as
shown by Sullivan and colleagues [19] for lung fibroblasts.
Moreover, TNF-α is capable of regulating the activity of
cardiac fibroblasts by decreasing collagen synthesis and
increasing matrix metalloproteinase activity [20]. However,
the role of this pleiotropic cytokine has not yet been defined
in the pathogenesis of post-traumatic joint contracture.
Based on the current data, we hypothesized that TNF-α is
likely to modulate the proliferation, differentiation, and
function of human joint capsule MFs and therefore may
unveil new therapeutic approaches for the prevention and
treatment of post-traumatic joint contracture. Here, we
describe the effect of TNF-α and its specific inhibitor inflix-
imab (IFX) on human MFs under controlled in vitro condi-
tions. We also report that the positive regulation of
prostaglandin E2 (PGE2) by TNF-α may play an important
role in the regulation of human joint capsule MF function.
Materials and methods
Human hip joint capsules were taken from 12 adult patients
(10 women and 2 men) with a mean age of 73 years (range
58 to 96) undergoing orthopedic surgery. The original inju-
ries were either displaced femoral neck fractures (n = 6) or
advanced osteoarthritis (n = 6) treated with hemi-hip or
total hip replacement. Physical examination in terms of the
range of motion (ROM) of the hip joints in patients with
fractures was not possible. However, based on the medical
history, there were no indications about restricted ROM
before the injury. The six patients operated on for osteoar-
thritis revealed a mean ROM of the hip joint as follows:
extension/flexion 0°-0°-108°, external/internal rotation 25°-
0°-20°, and abduction/adduction 50°-0°-20°. The patients
included neither were operated on before nor suffered from
rheumatic diseases or any conditions known to affect
wound healing.
For immunohistochemical comparison, contracted elbow
joint capsules were taken from four patients (3 women and
1 man; mean age of 61 years, range 56 to 65) undergoing
elbow surgery for post-traumatic stiffness. The original
injuries of the elbow patients were comminuted distal
humeral fractures treated primarily with open reduction and
internal fixation (ORIF) with plates. All of the patients
operated on had stiff elbows with severely limited ROM.
All of the functional experiments were performed with
cells isolated from hip joint capsules at least in triplicate
using triplicate or quadruplicate samples, whereas the num-
ber of measurements in probands varied for technical rea-
sons. The joint capsules used for the study were considered
to be surgical waste and otherwise would have been dis-
carded by the hospital. All experiments were approved by
the local ethics committee of Rheinland Pfalz (RLP
837.109.05 [4767]), and written informed consent was
obtained from every participating patient.
Cell isolation and culture of human myofibroblasts
All of the cultures and functional experiments were per-
formed with cells isolated from hip joint capsules. The joint
capsules were processed within 6 hours after excision. The
inner layer of the capsule, the synovial membrane, which
was loosely attached to the external fibrous capsule, was
carefully dissected from the fibrous tissue. For all of the
experiments, the outer layer of the joint capsule with the
fibrous tissue was used. The samples were rinsed in phos-
phate-buffered saline (PBS) (Dulbecco's PBS; Gibco Invit-
rogen Corporation, Karlsruhe, Germany) to remove blood
and fat residues and were gradually digested in a water bath
at 37°C with a mixture of type IV collagenase (1 mg/mL;
Sigma-Aldrich Chemie GmbH, Steinheim, Germany),
trypsin (2.5 mg/mL; Sigma-Aldrich Chemie GmbH), and
DNase I (deoxyribonuclease I) (2 mg/mL; Applichem
GmbH, Darmstadt, Germany). The specimens were filtered
through a cell strainer (100-μm mesh; BD Biosciences,
Heidelberg, Germany) after 45 and 90 minutes of incuba-
tion to obtain a single-cell suspension. The cell supernatant
was washed in serum-free Dulbecco's modified Eagle's
medium (DMEM) (Biochrom AG, Berlin, Germany) sup-
plemented with 10,000 U/mL penicillin G sodium and
10,000 μg/mL streptomycin sulfate (Gibco Invitrogen Cor-
poration, Karlsruhe, Germany) and finally centrifuged at
1.4 × 103 rpm for 5 minutes at 4°C. The cell pellet was
resuspended in DMEM supplemented with 10% heat-inac-
tivated fetal calf serum (FCS) (PAA Laboratories GmbH,
Pasching, Austria) and antibiotics, seeded into culture
flasks (Cellstar; Greiner Bio-One GmbH, Frickenhausen,
Germany), and incubated in a humidified atmosphere of 5%
CO2 at 37°C. Culture media were changed twice a week,
and preconfluent cells were passaged using accutase (PAA
Laboratories GmbH). Early-passage cells (passages 2 to 4)
were used for all experiments.Mattyasovszky et al, Arthritis Research & Therapy 2010, 12:R4
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Immunohistochemical evaluation of the joint capsule 
biopsies
Specimens of hip joint capsules and contracted elbow joint
capsules were fixed in neutral buffered formalin and
embedded in paraffin, and 5 μm-sections were routinely
stained with hematoxylin-eosin. MFs in the biopsies were
detected by immunohistochemical staining for α-SMA
using a monoclonal primary mouse anti-α-SMA antibody
(dilution 1:600; Progen Biotechnik GmbH, Heidelberg,
Germany; clone ASM-1) followed by a ready-to-use bioti-
nylated secondary antibody (Dako Real™ Link; Dako,
Glostrup, Denmark) and were visualized using the strepta-
vidin-peroxidase method with 3,3'-diaminobenzidine
(DAB) as chromogen. Immunohistochemical staining was
performed with an automated staining system (Dako Tech-
Mate 500 PLUS; Dako) using a standard ready-to-use kit.
Histological slides were evaluated under an Olympus light
microscope (BX45; Olympus, Hamburg, Germany) and
documented with a digital camera (Camedia C7070; Olym-
pus).
The expression of α-SMA in MF cultures originating
from hip joint capsules was verified using a monoclonal
mouse anti-human-α-SMA antibody (Dako, Hamburg, Ger-
many). The cells were seeded on histological cover slides at
a density of 25,000 cells/cm2, incubated for 24 hours, and
fixed with 3.7% paraformaldehyde (PFA). The slides were
incubated with the primary antibody for 2 hours, washed
with PBS, incubated with the secondary horseradish peroxi-
dase-coupled rabbit anti-mouse antibody (Dako), and
stained with DAB. Cell nuclei were counterstained with
Mayer's hemalun (Merck AG, Darmstadt, Germany). The
positive cells have been counted and calculated in subcon-
fluent cultures in five separate viewing fields under a light
microscope.
Immunofluorescence analysis of cell culturesMFs (4 ×
104 cells/well) were cultured on histological cover slides
with or without the cyclooxygenase-2 (COX2) inhibitor
diclofenac (10 μg/mL) in DMEM containing 1% FCS. The
expression of α-SMA and COX2 in MFs was determined
by immunofluorescence double-staining using a primary
monoclonal mouse anti-human-α-SMA antibody (dilution
1:50, clone 1A4; Dako; 45 minutes at room temperature)
and a primary mouse anti-human-COX2 antibody (1:100 in
saponin buffer, clone 33/COX2; BD Biosciences; 45 min-
utes at room temperature) in PFA-fixed cell cultures. Cells
were washed two times with cold PBS and incubated with
Texas Red-conjugated goat anti-mouse IgG2a for α-SMA
followed by fluorescein isothiocyanate-conjugated goat
anti-mouse IgG1 for COX2 (both from SouthernBiotech,
Birmingham, AL, USA) as a secondary antibody. Negative
controls were performed using respective isotype antibod-
ies. Cell nuclei were stained with Hoechst 33258 (dilution
1:10,000; Sigma-Aldrich Chemie GmbH) for 10 minutes at
room temperature in all experiments. Subsequently, the
slides were rinsed and embedded with Gel Mount (South-
ernBiotech) on glass cover slides. Cells were visualized
using a laser scanning confocal microscope (TCS SP-2;
Leica Microsystems, Bensheim, Germany).
Cell viability and proliferation
MFs were seeded into 96-well plates (Greiner Bio-One
GmbH) at a density of 10 × 104 cells/well and incubated in
150 μL of serum-supplemented DMEM (5% FCS, 1% peni-
cillin/streptomycin) for 48 hours. Thereafter, the cell layers
were washed with PBS and incubated for 24 hours in 150
μL of serum-free DMEM supplemented with 1% bovine
serum albumin (BSA). After 24 hours, the cells were
washed with PBS and incubated for 72 hours in 150 μL of
serum-free DMEM containing 1 or 10 ng/mL of TNF-α
(R&D Systems GmbH, Wiesbaden-Nordenstadt, Germany)
and/or the chimeric monoclonal antibody to TNF-α (10 μg/
mL IFX, generously provided by Centocor B.V., Leiden,
The Netherlands), and/or 10 μg/mL of the COX2 inhibitor
diclofenac (Figure 1). MFs cultured in 150 μL of serum-
free DMEM without any cytokine or inhibitor were used as
controls and named as the control group. Cell viability and
proliferation were measured using the colorimetric 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) assay (Promega GmbH, Mannheim, Germany).
After 72 hours, 30 μL of 0.5% MTT solution was added to
each well and incubated for 2 hours. The medium was
removed, and the dye was resolved with 100 μL of isopro-
panol (Hedinger GmbH & Co. KG, Stuttgart, Germany).
The optical density was measured at 570 nm (650 nm back-
ground) using an enzyme-linked immunosorbent assay
reader (Sunrise; Tecan Deutschland GmbH, Crailsheim,
Germany).
Collagen gel contraction assay
A three-dimensional (3D) collagen gel contraction model,
which is a well-accepted method for the estimation of the
cell-mediated contracture of the ECM in vitro in a 3D envi-
ronment [21], was established to estimate the contractile
forces exhibited by human hip joint MFs. The present pro-
tocol was established with primary human hip joint capsule
MFs by varying cell numbers, collagen gel volumes and
concentrations, time points of detachment, and different
concentrations of TGF-β1 as a positive control (data not
shown) [18,22,23]. Due to limited numbers of primary cells
from each donor, conditions requiring least possible cell
numbers and collagen volumes have been used.
Collagen gels were prepared using type I rat collagen (1.5
mg/mL; BD Biosciences, Bedford, MA, USA) in a 10-fold
Medium 199 concentrate, 7.5% NaHCO3, 1N NaOH (all
from Sigma-Aldrich Chemie GmbH), and distilled water.
The cells were resuspended in the gel solution and seeded
into 24-well plates at a density of 1.2 × 105 cells/300 μL.Mattyasovszky et al, Arthritis Research & Therapy 2010, 12:R4
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After 30 minutes, the solidified gels were incubated in 1
mL of serum-supplemented DMEM (10% FCS) for 48
hours. Thereafter, the gels were washed with PBS and incu-
bated for 24 hours in 1 mL of serum-free DMEM supple-
mented with 1% BSA. After a vigorous rinsing with PBS,
the cells were incubated for 72 hours in 1 mL of serum-free
DMEM containing TNF-α and/or IFX and/or diclofenac
according to Figure 1. MFs incubated in 150 μL of serum-
free DMEM only were used as controls and named as the
control group. Thereafter, the gels were released from the
culture plate with a pipette tip and cultured for a further 48
hours. Gel surfaces were scanned using the Canon 660 U
scanner (Canon Deutschland GmbH, Krefeld, Germany)
and calculated using the software ImageJ (National Center
for Biotechnology Information, Bethesda, MD, USA).
Simultaneous quantification of prostanoids using gas 
chromatography/mass spectrometry
Cells were cultured under the same conditions as described
in the previous section (Collagen gel contraction assay) and
challenged with TNF-α (1 or 10 ng/mL) as described above
or coincubated with TNF-α (10 ng/mL) and diclofenac (10
μg/mL) (Figure 1) after serum deprivation for 24 hours.
Cell culture medium supernatants were collected after 24,
48, 72, and 96 hours of culture and fresh medium was sub-
sequently added to the cultures at these time points. The
synthesis of prostaglandins E2 (PGE2), F1A (PGF1A), and
F2A (PGF2A) was determined by gas chromatography/mass
spectrometry (GC/MS). Sample aliquots were kept at -80°C
until further analysis. Concentrations of PGE2, PGF2A, and
the stable prostacyclin metabolite 6-keto-PGF1A were deter-
mined using GC/MS with minor modifications of a previ-
ously described method [24]. Briefly, cell culture
supernatants were spiked with approximately 10 ng of deu-
terated internal standards. The methoxime derivatives were
obtained by treatment with O-methylhydroxylamine hydro-
chloride in sodium acetate buffer. After acidification (pH
2.6), analytes were extracted and further derivatized to the
correspondent pentafluorobenzyl esters. Samples were puri-
fied by thin-layer chromatography, and two broad zones
with Rf 0.03 to 0.39 and 0.4 to 0.8 were scraped off and
eluted. After withdrawal of the organic solvent, trimethysi-
lyl ethers were prepared by reaction with bis(trimethylsi-
lyl)-trifluoroacetamide and thereafter injected into the GC/
MS/MS. We used a Finnigan (Thermo Fisher Scientific
GmbH, Dreieich, Germany) MAT TSQ700 GC/MS/MS,
equipped with a Varian 3400 gas chromatograph (Varian,
Inc., Palo Alto, CA, USA) and a CTC A200s autosampler
(CTC Analytics AG, Zwingen, Switzerland). GC of pros-
tanoid derivatives was carried out on a DB-1 (20 m, 0.25
The experimental setup to study the effect of tumor necrosis factor-alpha (TNF-α) on human joint capsule myofibroblasts Figure 1 The experimental setup to study the effect of tumor necrosis factor-alpha (TNF-α) on human joint capsule myofibroblasts. Seven 
different groups (a-g) were chosen in the study. Group (a) as the control was cultured without any cytokine or inhibitor. The cytokine or the inhibitor 
or both were added after 3 days of culture. On day 6, the MTT assay was performed and the three-dimensional (3D) collagen gels were released from 
the culture plate. After 48 hours, gel surfaces were calculated as indicated in Materials and methods. Diclo, diclofenac; IFX, infliximab; MTT, 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; RT-PCR, real-time polymerase chain reaction.
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mm ID, 0.25-μm film thickness) capillary column (Analyt
GmbH, Mühlheim, Germany) in the splitless injection
mode. GC/MS/MS parameters were exactly as described by
Schweer and colleagues [24].
Real-time polymerase chain reaction
Total RNA was extracted and purified from the cells fol-
lowing the 3D collagen gel contraction assay using Trizol
(Invitrogen Corporation) and RNeasy Micro Kits (Qiagen
GmbH, Hilden, Germany). Reverse transcription was per-
formed using 2 μg of RNA, M-MuLV-reverse transcriptase,
and hexamer primers (Peqlab Biotechnologie GmbH,
Erlangen, Germany). Real-time polymerase chain reactions
(PCRs) were performed using validated QuantiTect® prim-
ers (Qiagen GmbH) for α-SMA  (QT00088102),  collagen
type I (QT00037793), and 18S  RNA (QT00199367), as
well as the QuantiTect SYBR® Green quantitative PCR
Supermix (Invitrogen Corporation), an ABI 7300 device
(Applied Biosystems Deutschland GmbH, Darmstadt, Ger-
many), and the following thermal profile: 15 minutes at
95°C, 40 cycles of 15 seconds at 94°C, 30 seconds at 55°C,
and 35 seconds at 72°C, followed by a dissociation step to
confirm specificity of the reaction. The results were quanti-
fied using the 2ΔCt method and analyzed with the SDS 2.1
software (Applied Biosystems Deutschland GmbH). Mea-
surement values were indicated as fold expression of the
housekeeping gene 18S.
Western immunoblot
MFs (5 × 105 cells/medium culture flask) were cultured
with or without the COX2 inhibitor diclofenac (10 μg/mL)
in DMEM containing 1% FCS. Protein extraction was per-
formed using ice-cold lysis buffer (2 M Tris/HCl, pH 6.8 to
7.5 containing SDS, glycerol, and brome phenol blue). For
each sample, 10 μg of protein was denatured, subjected to
10% SDS-polyacrylamide gel electrophoresis, and blotted
to a polyvinylidene difluoride membrane (Millipore GmbH,
Schwalbach, Germany). The membranes were blocked in
Tris/Tween20 (TBST pH 7.4) containing 3% milk powder
for 1 hour and incubated with primary mouse anti-human
antibodies against α-SMA (dilution 1:100, clone 1A4;
Dako), COX2 (1:250, clone 33/COX2; BD Biosciences),
and  β-actin (dilution 1:10,000; Sigma-Aldrich Chemie
GmbH) overnight at 4°C. Immunoreactive bands were
detected with secondary horseradish peroxidase-conjugated
anti-mouse antibodies (diluted 1:5,000; Cell Signaling
Technology, Inc./New England Biolabs GmbH, Frankfurt
am Main, Germany) and visualized by enhanced chemilu-
minescence detection reagents (Western Lightning Plus Kit;
PerkinElmer Inc., Waltham, MA, USA) on autoradiograph
films (Agfa Curix HT 1.000 G Plus; Agfa-Gevaert N.V.,
Mortsel, Belgium).
Statistical analysis
All experiments and measurements were performed at least
in triplicate, and the number of measurements for each
experiment is indicated in the figure legends. For statistical
analysis, the SPSS 10.07 software (SPSS Inc., Chicago, IL,
USA) was used. The data distribution was defined by medi-
ans ± quartiles. For fold comparisons, the measurement val-
ues were normalized to the respective individual replicate
samples of the control group and transformed to a log2
scale. The data distribution was presented in box plots. For
multiple comparisons, the paired non-parametric Wilcoxon
test was performed. Differences were considered to be sta-
tistically significant for P < 0.05 and depicted by *P < 0.05,
**P < 0.01, and ***P < 0.001.
Results
Contracted elbow joint capsules reveal high numbers of α-
SMA-positive cells
The histological analysis of the biopsies from hip joint cap-
sules yielded a comparable pattern for every patient stud-
ied. Beneath the synovial membrane consisting of a
monolayer or a multilayer of synoviocytes as well as loose
soft tissue with small blood vessels, a thin layer of fat tissue
was observed. The layers underneath showed a regularly
oriented fiber-rich ECM with low numbers of spindle-like
cells that were negative for α-SMA (Figure 2a). The smooth
muscle cells of the blood vessels reacted strongly positive
with antibodies against α-SMA and thus were used as an
internal positive control (Figure 2b). In contrast, the speci-
mens of contracted elbow joint capsules were interspersed
with small spindle-like cells that were strongly positive for
α-SMA by immunohistochemistry (Figure 2c, d). Each
patient studied with contracted capsule revealed compara-
ble α-SMA staining pattern. The soft tissue layer showed a
more irregular, partially sclerosing fibrous tissue, occasion-
ally representing mucoid degeneration and lymphocytic
infiltrates.
Mature joint capsule fibroblasts in culture express α-SMA
Only a few days after incubation, the typical spindle-like
shape of in vitro cultured fibroblasts (Figure 3a) increas-
ingly changed toward the phenotype of stellate cells (Figure
3b), which were strongly positive for the MF marker α-
SMA (Figure 3c, d). The positive staining for α-SMA
focused on regions of intracellular stress fibers, a hallmark
of MFs. Before the start of the experiments, the preconflu-
ent cell cultures contained almost 80% to 100% α-SMA-
positive cells (Figure 3d).
The pro-inflammatory cytokine TNF-α induces 
myofibroblast proliferation
Upon addition of TNF-α, MF cultures revealed a dose-
dependent increase of cell viability and proliferation (Fig-
ure 4). Compared with the control group, cell proliferationMattyasovszky et al, Arthritis Research & Therapy 2010, 12:R4
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was significantly induced by 1 ng/mL TNF-α and did not
notably increase proliferation at the higher concentration of
the cytokine (Figure 4 and Table 1). The proliferative effect
of TNF-α (1 or 10 ng/mL) was significantly reduced by its
blocker IFX (10 μg/mL). MFs cultured with IFX only
showed no significant differences in terms of cell viability
compared with the control group (Figure 4 and Table 1).
Interestingly, coincubation of MFs with TNF-α (10 ng/mL)
and the COX2 inhibitor diclofenac (10 μg/mL) resulted in a
significant inhibition of TNF-α-induced cell proliferation.
TNF-α inhibits contractile forces exhibited by 
myofibroblasts
In comparison with the controls, the addition of 1 ng/mL
TNF-α significantly inhibited collagen gel contraction as
the gel surfaces of this group were significantly larger (Fig-
ure 5a, b and Table 1). This effect is indicative of reduced
contractile forces exhibited by MFs. The inhibition of colla-
gen gel contracture was even stronger upon the application
of 10 ng/mL TNF-α. This inhibitory effect of the cytokine
was significantly blocked by IFX as the surface areas of the
collagen gels reversed to a dimension that was comparable
to the controls. MFs cultured with IFX only showed no sig-
nificant change of contraction behavior compared with the
controls (Figure 5a, b and Table 1). The addition of
diclofenac to collagen gels that were stimulated with 10 ng/
mL TNF-α before significantly reversed the TNF-α effect
and promoted ECM contraction (Figure 5a, b and Table 1).
TNF-α suppresses α-SMA and collagen type I gene 
expression in myofibroblasts
Whereas the lower concentration of TNF-α revealed low
inhibitory effects on gene expression of α-SMA and colla-
gen type I, the expression of these two transcripts was sig-
nificantly downregulated upon addition of 10 ng/mL TNF-
α (Figure 6a, b and Table 1). This suppressive effect on
Expression of the myofibroblast marker alpha-smooth muscle actin (α-SMA) in hip joint and contracted elbow joint capsules Figure 2 Expression of the myofibroblast marker alpha-smooth muscle actin (α-SMA) in hip joint and contracted elbow joint capsules. Bi-
opsy sections were stained as indicated in Materials and methods. (a) Hematoxylin-eosin staining of hip joint capsules revealed parallel orientation of 
the collagen fibers and small spindle-like fibrocytes. (b) The immunohistochemical detection of α-SMA in hip joint capsules showed that only smooth 
muscle cells associated with blood vessels were positive for this marker (arrows). (c, d) Arrows indicate multiple positive cells in the immunohis-
tochemical staining for α-SMA (brown dye) in contracted elbow joint capsule which were not linked to blood vessels. Scale bars = 100 μm.Mattyasovszky et al, Arthritis Research & Therapy 2010, 12:R4
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gene expression of these two markers was blocked by IFX,
as the expression of both genes reverted almost to the level
of the control group, and was significantly reduced by the
COX2 inhibitor diclofenac. However, IFX alone did not
influence the gene expression of α-SMA and collagen type I
(Figure 6a, b and Table 1).
The effects of TNF-α on myofibroblasts are mediated by 
prostaglandin E2 synthesis
Using immunfluorescence staining and Western blot analy-
sis, we found that α-SMA-positive human MFs did express
the enzyme COX2 (Figure 7a, b), which is required for the
synthesis of PGE2. GC/MS analysis revealed a dramatic
time-dependent increase of PGE2 concentrations in MF cul-
tures upon stimulation with TNF-α. Low and high concen-
trations of TNF-α yielded a comparable synthesis level of
PGE2, with a peak response after 24 and 48 hours (Figure
7c). Interestingly, the syntheses of both PGF1A and PGF2A
(data not shown) were not affected by TNF-α. The PGE2
levels in the control group were as low as in culture
medium without cells, indicating that only low levels of
PGE2  were synthesized during basal culture conditions.
Coincubation of MFs with TNF-α (10 ng/mL) and
diclofenac (10 μg/mL) resulted in a complete abrogation of
the TNF-α-mediated increase in PGE2 synthesis (Figure
7c), which was associated with a significant decline in
TNF-α-induced effects on cell proliferation (Figure 4),
ECM contraction (Figure 5b), and collagen type I gene
expression (Figure 6b). Although the TNF-α-mediated inhi-
bition of α-SMA gene expression was also attenuated by
coincubation with diclofenac, the treatment with diclofenac
did not reduce the overall effects of TNF-α o n  M F  c e ll
function to the same extent as IFX (Figure 6a, b). Further-
more, treatment of MFs with 10 μg/mL diclofenac only did
not reveal any significant effects on the protein expression
of COX2 or α-SMA (Figure 7a, b).
Phenotype of the cells used in this study Figure 3 Phenotype of the cells used in this study. (a) Early cultures of fibroblasts were characterized by a typical spindle-like shape (arrows) and 
gradually matured into myofibroblasts (b) revealing typical stellate-shaped morphology (arrows) over the course of culture. (c, d) The myofibroblast 
cell marker alpha-smooth muscle actin was detected in confluent cell cultures as indicated in Materials and methods. Scale bars = 100 μm.Mattyasovszky et al, Arthritis Research & Therapy 2010, 12:R4
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Discussion
Tissue healing is a complex process that requires activation,
migration, and differentiation of various cells that are capa-
ble of ECM synthesis and later wound repair. Therefore,
transformation of fibroblasts to contractile MFs is generally
accepted to be a key element in early wound healing. In this
study, we could show that in contrast to hip joint capsules
of patients who did not suffer from any condition known to
affect the ROM of the respective joints, the number of α-
SMA-positive MFs is notably increased in the biopsies of
contracted joint capsules after injury. To therapeutically
counteract an excessive ECM synthesis and contraction, it
is most important to understand the molecular pathways
that regulate the activation and function of MFs.
Cell viability and proliferative capacity of myofibroblasts upon tumor necrosis factor-alpha (TNF-α) treatment Figure 4 Cell viability and proliferative capacity of myofibroblasts upon tumor necrosis factor-alpha (TNF-α) treatment. The effect of the cy-
tokine TNF-α (1 and 10 ng/mL) in the presence or absence of the TNF-α inhibitor infliximab (IFX) (10 μg/mL) or the cyclooxygenase inhibitor diclofenac 
(Diclo) on myofibroblasts was analyzed by using the MTT cell viability assay. Data are representative of nine (Table 1) independently performed TNF-
α ± IFX experiments and seven independently performed TNF-α ± diclofenac experiments with four replicate measurements from each individual 
patient sample (n = 68 for the 'control' and 'TNF-α 10 ng/mL' groups, n = 28 for the 'TNF-α 10 ng/mL+diclofenac' group, and n = 36 for all other 
groups). Results are plotted as fold changes of the respective samples in the control group according to the paired non-parametric Wilcoxon test used 
for the statistical analysis. *P < 0.05, ***P < 0.001. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide.Mattyasovszky et al, Arthritis Research & Therapy 2010, 12:R4
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Table 1: Data distribution and statistical analysis
Fold change of the respective patient sample in the
control group (log2)
Experiment Group Numbera 25th quartile Median 75th quartile P value
MTT assay B:  1  ng/mL
TNF-α
36 0.37 0.60 0.85 B vs. A: <0.001
C: 10 ng/mL
TNF-α
68 0.43 0.60 0.85 C vs. A: <0.001
D: 1 ng/mL
TNF-α + 10 μg/
mL IFX
36 -0.03 0.13 0.39 D vs. B: <0.001
E: 10 ng/mL
TNF-α + 10 μg/
mL IFX
36 0.21 0.38 0.78 E vs. C: <0.001
F: 10 μg/mL
IFX
36 -0.21 0.02 0.30 F vs. A: 0.2
G: 10 ng/mL
TNF-α + 10 μg/
mL Diclo
28 0.02 0.16 0.30 G vs. C: 0.031
3D collagen
gel
B: 1 ng/mL
TNF-α
40 -0.01 0.23 0.46 B vs. A: <0.001
C: 10 ng/mL
TNF-α
52 0.71 0.90 1.47 C vs. A: <0.001
D: 1 ng/mL
TNF-α + 10 μg/
mL IFX
40 -0.44 -0.22 0.04 D vs. B: <0.001
E: 10 ng/mL
TNF-α + 10 μg/
mL IFX
40 -0.35 -0.14 0.19 E vs. C: <0.001
F: 10 μg/mL
IFX
40 -0.23 -0.01 0.15 F vs. A: 0.6
G: 10 ng/mL
TNF-α + 10 μg/
mL Diclo
40 0.04 0.17 0.67 G vs. C: 0.002
qPCR
α-SMA B: 1 ng/mL
TNF-α
8 -1.01 -0.14 1.15 B vs. A: 0.8
C: 10 ng/mL
TNF-α
25 -6.29 -5.64 -3.48 C vs. A: <0.001
D: 1 ng/mL
TNF-α + 10 μg/
mL IFX
8 -1.20 -0.004 0.90 D vs. B: 0.4
E: 10 ng/mL
TNF-α + 10 μg/
mL IFX
8 -0.63 -0.50 0.10 E vs. C: 0.01Mattyasovszky et al, Arthritis Research & Therapy 2010, 12:R4
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F: 10 μg/mL
IFX
8 -0.45 -0.32 -0.12 F vs. A: 0.5
G: 10 ng/mL
TNF-α + 10 μg/
mL Diclo
9 -4.85 -4.32 -3.74 G vs. C: 0.015
Collagen type I B: 1 ng/mL
TNF-α
8 -0.36 -0.007 0.59 B vs. A: 1.0
C: 10 ng/mL
TNF-α
17 -4.35 -3.47 -3.00 C vs. A: 0.01
D: 1 ng/mL
TNF-α + 10 μg/
mL IFX
8 -0.93 -0.30 0.54 D vs. B: 0.2
E: 10 ng/mL
TNF-α + 10 μg/
mL IFX
8 -1.03 -0.20 0.50 E vs. C: 0.01
F: 10 μg/mL
IFX
8 -1.60 -0.009 0.27 F vs. A: 0.6
G: 10 ng/mL
TNF-α + 10 μg/
mL Diclo
9 -2.21 -1.84 -0.93 G vs. C: 0.015
aNumber of measurements. 3D, three-dimensional; α-SMA, alpha-smooth muscle actin; Diclo, Diclofenac; IFX, infliximab; MTT, 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; qPCR, quantitative polymerase chain reaction; TNF-α, tumor necrosis factor-alpha.
Table 1: Data distribution and statistical analysis (Continued)
Over the years, it has become evident that MFs arise from
a variety of sources and may develop different phenotypes
according to the involved organ and the physiological or
pathological situation [9,18,25,26]. With respect to the cur-
rent literature, the origin of the cells as well as their
cytokine environment [9] are decisive for understanding
MF development and regulation. Although TNF-α was
shown to mediate different target cells in the pathogenesis
of fibrocontractive disorders, the role of this cytokine in the
pathogenesis of post-traumatic joint contracture has not
been defined yet.
Here, we describe in detail the functional effect of TNF-α
on human MFs that differentiated from fibroblasts isolated
from hip joint capsules. Although it has been previously
described that normal elbow capsules can be obtained from
organ donors [7] for limited resources, we did not take cap-
sules of organ donors as a source of MFs for our functional
experiments. We could demonstrate that TNF-α is capable
of inducing cell viability and proliferation in MF cultures.
This effect was already present at a low concentration of the
cytokine. However, the stimulation of the cells with higher
concentrations of TNF-α did not result in additional
increase of the cell proliferation rate, presumably due to
complete receptor saturation. Furthermore, as the prolifera-
tive effect of TNF-α was significantly reduced by its inhibi-
tor IFX, we conclude that cell proliferation was specifically
mediated by this cytokine. On the other hand, we did not
observe any significant effects of IFX without TNF-α on
cell viability and proliferation in MF cultures. Although our
results are consistent with previous findings that TNF-α has
the potential to induce proliferation of fibroblasts and MFs
[27,28], there is also significant evidence of the antiprolif-
erative effect of TNF-α as previously described in liver
MFs, the hepatic stellate cells (HSCs) [29]. Such differ-
ences in regulation processes emphasize once more the con-
cept of tissue-specific regulation of MF function.
Despite this positive stimulatory effect on cell prolifera-
tion, we found that the contractile forces of MFs were sig-
nificantly inhibited upon application of TNF-α according to
a significant inhibition of α-SMA gene expression. This fact
supports the hypothesis that the fibroblast-to-MF transition
may be affected by TNF-α. Studies in the past revealed that
the contractile function of the MFs is linked to the expres-
sion of α-SMA and different ECM proteins like collagen
type I. According to a previous study on rat lung fibroblasts
[30], we found that the functional inhibition of ECM con-
traction by human joint capsule MFs upon TNF-α treatment
was clearly associated with a significant downregulation of
α-SMA and collagen type I gene expression. Interestingly,
whereas the lower concentration of TNF-α induced prolifer-Mattyasovszky et al, Arthritis Research & Therapy 2010, 12:R4
http://arthritis-research.com/content/12/1/R4
Page 11 of 16
The effect of tumor necrosis factor-alpha (TNF-α) on collagen gel contraction Figure 5 The effect of tumor necrosis factor-alpha (TNF-α) on collagen gel contraction. (a) Images of the three-dimensional collagen gel con-
traction assay shown are representative of all (Table 1) independently performed experiments. Three collagen gels of each group are shown before 
(day 6) and after (day 8) releasing the gels from the culture plates, revealing distinct differences in gel contraction in the groups upon TNF-α and inf-
liximab (IFX) or diclofenac (Diclo) coincubation. White circles in the first rows of the plates illustrate the margins of the gels comprising the gel surface 
areas. (b) Gel surfaces of the floating gels in the presence or absence of TNF-α (1 and 10 ng/mL), the TNF-α inhibitor IFX (10 μg/mL), or diclofenac (10 
μg/mL) were scanned and calculated as described in Materials and methods. Data are representative of 10 (Table 1) independently performed TNF-α 
± IFX experiments and three independently performed TNF-α ± diclofenac experiments with four replicate measurements from each individual pa-
tient sample (n = 52 for the 'control' and 'TNF-α 10 ng/mL' groups, n = 12 for the 'TNF-α 10 ng/mL+diclofenac' group, and n = 40 for all other groups). 
Results are plotted as fold changes of the respective samples in the control group according to the paired non-parametric Wilcoxon test used for the 
statistical analysis. **P < 0.01, ***P < 0.001.Mattyasovszky et al, Arthritis Research & Therapy 2010, 12:R4
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Tumor necrosis factor-alpha (TNF-α) downregulates gene expression of the myofibroblast marker alpha-smooth muscle actin (α- SMA) and the extracellular matrix protein collagen type I Figure 6 Tumor necrosis factor-alpha (TNF-α) downregulates gene expression of the myofibroblast marker alpha-smooth muscle actin (α-
SMA) and the extracellular matrix protein collagen type I. The mRNA expression of α-SMA (a) and collagen type I (b) was determined for every group 
(Figure 1) by quantitative real-time polymerase chain reaction. The mRNA level of α-SMA of every group examined was normalized to the housekeep-
ing gene 18S. Data are representative of four (Table 1) independently performed TNF-α ± infliximab (IFX) experiments and TNF-α ± diclofenac (Diclo) 
experiments with duplicate measurements from each individual patient sample (n = 16 for the 'control' and 'TNF-α 10 ng/mL' groups and n = 8 for 
all other groups). Results are plotted as fold changes of the respective samples in the control group according to the paired non-parametric Wilcoxon 
test used for the statistical analysis. *P < 0.05, **P < 0.01, ***P < 0.001.
ation and significant inhibition of contractile forces in MFs
in the collagen gels, we did not find a significant inhibition
of α-SMA and collagen I gene expression at the lower level
of this cytokine. Previous studies provided evidence that
the decrease in collagen synthesis occurred without a
change in cell number [20], indicating that the inhibition of
the ECM contraction might be due to decreased synthesis at
the cellular level. The synthesis of collagen is a hallmark of
the strict regulation of MFs by a complex cytokine environ-
ment. Different studies revealed that the pro-inflammatory
cytokines TNF-α and IL-1β have profound effects on colla-
gen metabolism in fibroblasts in vitro by downregulating
the synthesis of collagen [18,20,31]. Singer and Clark [32]
demonstrated that TNF-α was able to modulate ECM turn-
over by inhibition of protein synthesis and activation of
matrix metalloproteinases. Moreover, there is evidence that
TNF-α is capable of antagonizing TGF-β1-induced upregu-
lation of type I and III collagen expression in mouse fibro-
blasts [33]. Thus, the antagonistic relationship between
TGF-β1 and TNF-α may play an important role in main-
taining tissue homeostasis and ECM deposition, whereas
the cytokine network that modulates this process is presum-
ably more complex. Based on these data, we believe that
the inhibition of ECM contraction by TNF-α might be due
to a functional inhibition of human MFs both by a reduced
expression level of α-SMA as well as by the decrease of
ECM protein expression.
The antiproliferative impact of TNF-α in human HSCs,
the MFs of the liver, was previously described to be medi-
ated by increased formation of nuclear factor-kappa-B (NF-
κB) DNA-binding complexes [29]. Interestingly, the pro-
moter region of the COX2 gene possesses specific binding
sites for the NF-κB complexes. Thus, treatment of HSCs
with TNF-α was shown to positively regulate gene expres-
sion of COX2 and this accounted for basal COX activity in
these cells [29]. On the other hand, exogenous treatment of
fetal and adult lung fibroblast with PGE2 was reported to
inhibit TGF-β1-induced expression of α-SMA and collagen
type I by increasing cAMP production [34]. Based on these
findings, we hypothesized that the effects of TNF-α on
human joint capsule MFs may be mediated even by endoge-
nous prostaglandin synthesis. Here, we could clearly show
that human joint capsule MFs express COX2 under in vitro
conditions (Figure 7a, b) and significantly upregulate syn-
thesis of PGE2 (Figure 7c), but not PGF1A and PGF2A, upon
TNF-α treatment. The TNF-α-mediated increase of PGE2
levels was completely blocked by the non-specific COX
inhibitor diclofenac administered in a concentration that isMattyasovszky et al, Arthritis Research & Therapy 2010, 12:R4
http://arthritis-research.com/content/12/1/R4
Page 13 of 16
Tumor necrosis factor-alpha (TNF-α) modulates the synthesis of prostaglandin E2 (PGE2) in alpha-smooth muscle actin (α-SMA)- positive myofibroblasts (MFs) Figure 7 Tumor necrosis factor-alpha (TNF-α) modulates the synthesis of prostaglandin E2 (PGE2) in alpha-smooth muscle actin (α-SMA)-
positive myofibroblasts (MFs). (a) Immunofluorescent staining of cyclooxygenase-2 (COX2) (first panel, green, fluorescein isothiocyanate filter) and 
α-SMA (second panel, red, Texas Red filter) in MF cultures with or without the COX2 inhibitor diclofenac (Diclo). The third panel illustrates merged 
images of Höchst 33248-stained nuclei (blue, DAPI filter) as well as immunofluorescence for COX2 and α-SMA. α-SMA-positive MFs derived from hip 
joint capsules express the enzyme COX2. The fourth panel shows merged images of the negative controls. Scale bars are shown in the lower right 
corner of each panel. (b) MFs of three different donors were exposed to 10 μg/mL diclofenac. The expression of α-SMA (45 kDa), COX2 (72 kDa), and 
β-actin (42 kDa) as a loading control was evaluated by using Western blots. A characteristic double band for the COX2 protein corresponding to the 
expected molecular weight represents different glycosylated forms of the enzyme. (c) Gas chromatographic/mass spectrometric analysis revealed a 
time-dependent increase of PGE2 concentration in MF cultures upon TNF-α stimulation with a peak after 24 and 48 hours. This effect was completely 
blocked by diclofenac. DAPI, 4'-6-diamidino-2-phenylindole.
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comparable to therapeutic but not toxic levels in humans
[35]. Although some functional parameters of MFs were
nearly completely restored by coincubation of TNF-α-
treated cells with diclofenac (Figure 7c), the gene expres-
sions of α-SMA and collagen type I (Figure 6a, b) were still
significantly inhibited, suggesting that the effect of TNF-α
could not be blocked at this concentration to the same
extent as by the neutralizing antibody IFX.
Conclusions
In the present work, TNF-α modified the function of human
MFs, suggesting a regulative effect of TNF-α during the
wound healing. Whereas TNF-α had a high proliferative
effect on MFs at low concentrations already, it functionally
inhibited the contraction of the ECM and downregulated
the gene expression of α-SMA and collagen type I. As these
two genes were only significantly inhibited upon high con-
centrations of TNF-α stimulation compared with the control
group, we conclude that TNF-α might have a dual, dose-
dependent modulatory effect on MFs at the beginning of a
healing process. The effects of TNF-α on human joint cap-
sule MFs (positive for the marker COX2) were associated
with a significant increase of PGE2 synthesis, suggesting its
crucial role in the regulation of this cell type. Accordingly,
they were almost completely prevented by the inhibition of
COX2 with diclofenac at a clinically relevant concentra-
tion. Our current concept of MF modulation is summarized
and illustrated in Figure 8. Further evaluation is required in
order to address the hypothesis that cell proliferation and
MF function may be altered in clinical use by therapeuti-
cally applied immunomodulatory treatments. This estab-
lished culture and 3D model potentially provide a basis for
further investigations to shed new light on this complex
cytokine network and to develop alternative non-operative
treatment strategies of fibroconnective pathologies like
post-traumatic contracture. Prophylactic pharmacological
intervention could provide new specific treatment options
for post-traumatic contractures and other fibroconnective
pathologies.
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3D: three-dimensional; α-SMA: alpha-smooth muscle actin; BSA: bovine serum
albumin; COX2: cyclooxygenase-2; DAB: 3,3'-diaminobenzidine; DMEM: Dul-
Illustrative concept of myofibroblast (MF) modulation by tumor necrosis factor-alpha (TNF-α) Figure 8 Illustrative concept of myofibroblast (MF) modulation by tumor necrosis factor-alpha (TNF-α). TNF-α inhibits extracellular matrix 
(ECM) contraction by the downregulation of alpha-smooth muscle actin (α-SMA) and collagen type I expression in MFs presumably by promoting pros-
taglandin E2 (PGE2) synthesis. Both infliximab (IFX) by blocking TNF-α and diclofenac by inhibiting cyclooxygenase-2 (COX2) might enhance ECM con-
traction. NF-κB, nuclear factor-kappa-B.
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becco's modified Eagle's medium; ECM: extracellular matrix; FCS: fetal calf
serum; GC/MS/MS: gas chromatography/mass spectrometry/mass spectrome-
try; HSC: hepatic stellate cell; IFX: infliximab; MF: myofibroblast; MTT: 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; NF-κB: nuclear factor-
kappa-B; PBS: phosphate-buffered saline; PCR: polymerase chain reaction; PFA:
3.7% paraformaldehyde; PGE2: prostaglandin E2; PGF: prostaglandin F; ROM:
range of motion; TGF-β1: transforming growth factor-beta 1; TNF-α: tumor
necrosis factor-alpha.
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